Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Fred SaadKim N ChiNeal D ShoreJulie N GraffEdwin M PosadasJean-Baptiste LattoufByron M EspinaEugene ZhuAlex YuAnasuya HazraMarc De MeulderRao N V S MamidiBranislav BradicPeter FrancisVinny HayrehArash Rezazadeh KalebastyPublished in: Cancer chemotherapy and pharmacology (2021)
NCT02924766 (ClinicalTrials.gov).
Keyphrases